title: The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
abstract: We have evaluated the use of CD138+ positively selected bone marrow samples to identify a molecular target for minimal residual disease assessment by polymerase chain reaction (PCR) in 25 untreated patients with multiple myeloma. A fraction of each sample was used for CD138+ selection, and the rest served as a reference control. VDJH, DJH, and Kde gene rearrangements were tested for amplification according to the BIOMED-2 Concerted Action. PCR products were directly sequenced in an automated ABI 3130 DNA sequencer using Big-Dye terminators. Within the CD138+ selected group, VDJH rearrangements were detected in all cases (100 %), DJH in 16 (64 %), and Kde in 18 (72 %) cases; whereas in the control samples, VDJH, DJH, and Kde rearrangements were detected in 19 (76 %), 11 (44 %), and 12 (48 %) cases, respectively. After sequencing, 24 (96 %) cases within the CD138+ group had a PCR target for MRD detection compared with 15 (60 %) cases in the control group. We conclude that the use of CD138+ positively selected bone marrow samples increases the applicability of minimal residual disease studies by PCR in patients with multiple myeloma.
authors.affiliation: Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.
authors.forename: Noemí
authors.initials: N
authors.lastname: Puig
authors.forename: María E
authors.initials: ME
authors.lastname: Sarasquete
authors.forename: Miguel
authors.initials: M
authors.lastname: Alcoceba
authors.forename: Ana
authors.initials: A
authors.lastname: Balanzategui
authors.forename: María C
authors.initials: MC
authors.lastname: Chillón
authors.forename: Elena
authors.initials: E
authors.lastname: Sebastián
authors.forename: Luis A
authors.initials: LA
authors.lastname: Marín
authors.forename: Marcos González
authors.initials: MG
authors.lastname: Díaz
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: Ramón García
authors.initials: RG
authors.lastname: Sanz
mesh_terms: D001853:Bone Marrow / Q000473:pathology*; D001856:Bone Marrow Examination / Q000379:methods*; D002469:Cell Separation / Q000379:methods*; D002999:Clone Cells / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics; D015322:Gene Rearrangement, B-Lymphocyte; D006801:Humans; D009101:Multiple Myeloma / Q000473:pathology*; D009194:Myeloma Proteins / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods*; D053668:Syndecan-1 / Q000032:analysis*; D060152:V(D)J Recombination
chemical_list: D004273:DNA, Neoplasm; D009194:Myeloma Proteins; C508241:SDC1 protein, human; D053668:Syndecan-1